// App-Quantinova.ai

602 : Deletions In TBL1XR1 Results In Glucocorticoid Resistance By Decreasing Glucocorticoid Signaling In Childhood B-Lymphoblastic Leukemia

Researchers

Presenter

  • Courtney L Jones

Principal Investigators

  • Teena Bhatla

  • Jinhua Wang

  • Wallace Bourgeois

  • Bitterman S Danielle

  • Elizabeth A. Raetz

  • Debra J. Morrison

  • David T. Teachey

  • Garabedian Michael

  • William L. Carroll

Medical Centers

  • Department of Chemistry, New York University, New York, NY

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

  • Department of Pediatric Hematology-Oncology, New York University Medical Center, New York, NY

  • Department of Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

  • Cancer Institute, New York University, New York, NY

  • New York University Cancer Institute, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Glucocorticoid resistance

  • B lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Interleukin 21 Receptor

  • Transducin Beta Like 1 X-Linked Receptor 1

  • Zinc finger E-box binding homeobox 1

  • Thioredoxin-interacting protein

Drug/Treatment

  • Glucocorticoid

  • Prednisolone

  • Tabloid

  • Doxorubicin

  • Etoposide

  • Etoposide phosphate

  • Vorinostat

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved